Compare PRU & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRU | ONC |
|---|---|---|
| Founded | 1875 | 2010 |
| Country | United States | Switzerland |
| Employees | 36824 | 12000 |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9B | 31.4B |
| IPO Year | N/A | N/A |
| Metric | PRU | ONC |
|---|---|---|
| Price | $98.64 | $294.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $103.71 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 2.1M | 178.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $723.76 |
| Revenue Next Year | $3.06 | $15.04 |
| P/E Ratio | ★ $10.44 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $91.89 | $228.93 |
| 52 Week High | $119.76 | $385.22 |
| Indicator | PRU | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 41.83 |
| Support Level | $95.76 | $283.56 |
| Resistance Level | $105.05 | $300.00 |
| Average True Range (ATR) | 2.07 | 6.64 |
| MACD | 0.08 | -2.11 |
| Stochastic Oscillator | 58.69 | 11.89 |
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2025 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 39% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 11% of its 2025 adjusted earnings. PGIM had around $1.47 trillion in assets under management at the end of fourth-quarter 2025.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.